| Search by tag or site | Login to my blog ? Start my own blog |
![]() |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Profile: Gentris Corporation
Posted on 06/25/2007 08:59:53 | Link | Post Comment
BioHealth Investor Company Directory Profile
GENTRIS CORPORATION
133 Southcenter Court
Suite 400
Morrisville, NC 27560 USA
919.465.0100 Phone
919.465.0554 Fax
Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).
For every 5,000 drug candidates that enter pre-clinical testing, the Food and Drug Administration will approve only one. As a result, pharmaceutical organizations are under pressure to reduce costs and to address the key reasons for drug failure - ADRs, lack of efficacy and unfavorable pharmacokinetics/drug metabolism properties.
ADRs are currently the fourth leading cause of death and the fifth leading cause of illness in the United States. Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients' exposure to drugs based on their drug-response genotype. This can offer the added benefit of making drugs that might otherwise not be approved or withdrawn to become available to patients with compatible pharmacogenomic profiles. Other benefits include shorter and more focused clinical trials that offer the promise of getting drugs to market faster, with higher safety profiles and at lower cost.
Company Mission
Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
GENTRIS CORPORATION133 Southcenter Court
Suite 400
Morrisville, NC 27560 USA
919.465.0100 Phone
919.465.0554 Fax
Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).
For every 5,000 drug candidates that enter pre-clinical testing, the Food and Drug Administration will approve only one. As a result, pharmaceutical organizations are under pressure to reduce costs and to address the key reasons for drug failure - ADRs, lack of efficacy and unfavorable pharmacokinetics/drug metabolism properties.
ADRs are currently the fourth leading cause of death and the fifth leading cause of illness in the United States. Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients' exposure to drugs based on their drug-response genotype. This can offer the added benefit of making drugs that might otherwise not be approved or withdrawn to become available to patients with compatible pharmacogenomic profiles. Other benefits include shorter and more focused clinical trials that offer the promise of getting drugs to market faster, with higher safety profiles and at lower cost.
Company Mission
Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
![]()
- Real Estate Marketing Blog
- Morpheus Trading
- Alpha Trends
- Millionaire Now! by Larry Nusbaum
- Random Roger's Big Picture
- Biiwii.com Notes
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]












<< My Home | TheMoneyBlogs Home